U.S. markets closed

Samsung Biologics Co.,Ltd. (207940.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
750,000.00-25,000.00 (-3.23%)
At close: 3:30PM KST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close775,000.00
Open763,000.00
Bid752,000.00 x 0
Ask753,000.00 x 0
Day's Range750,000.00 - 764,000.00
52 Week Range352,000.00 - 883,000.00
Volume121,246
Avg. Volume163,507
Market Cap49.624T
Beta (5Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateApr 19, 2021 - Apr 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est499,500.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
      PR Newswire

      Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

      Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the global market.

    • Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales
      PR Newswire

      Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales

      Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excellence in overcoming various challenges and global uncertainties amid the COVID-19 pandemic throughout the year.

    • Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference
      PR Newswire

      Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference

      Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference. John Rim, newly appointed President and CEO, unveiled a multidimensional business plan for the company to further expand as a major player in the biopharmaceutical industry, bolstering its rapidly expanding CDMO business with a greater global footprint, continued advancements in its biosimilars subsidiary, and ultimately new drug development.